Opdivo is now the first and only programmed death-1 (PD-1) inhibitor approved for a hematologic malignancy in the European Union (EU). It is the company’s second immuno-oncology agent
The Swiss drugmaker exercised its right to buy Selexys following a successful phase II trial to evaluate the latter’s investigational drug SelG1 for reducing vaso-occlusive pain crises in
APL is a rare type of blood cancer that can kill within hours or days if it is not treated. About 1,500 to 2,000 people in Europe are
The phase 2 trial, dubbed Evolve, involved 14 patients ages 40 to 80 years who were undergoing percutaneous transluminal renal angioplasty and stenting. The study's endpoints were a change in
According to approval from the FDA’s Center for Biologics Evaluation and Research, the treatment can now be used among infants of six months or older. Before this approval,
CCH is marketed as XIAFLEX in the US and Xiapex in Europe. BioSpecifics' partner Endo International carried out the phase 2b trial, which enrolled 375 adult women with moderate or severe
The company submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the investigational anti-interleukin (IL)-23 monoclonal antibody. Guselkumab targets IL-23, a protein
Sirukumab is being co-developed by Janssen Biologics (Ireland) and GSK. The companies unveiled results from two pivotal phase 3 studies assessing subcutaneous (SC) sirukumab, a human anti-interleukin (IL)-6
In the global phase 3, multicenter, randomized 24-week, double-blind, placebo-controlled Strive study, 955 patients were randomized to receive once-monthly subcutaneous placebo or erenumab (70 mg or 140 mg)
The trial, Expedition-4, enrolled 104 patients including 85 who were receiving dialysis at enrollment, 20 with compensated cirrhosis and 44 who were not cured with sofosbuvir with ribavirin
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.